Loading clinical trials...
Loading clinical trials...
Phase II Study Therasphere® (Yttrium-90) in Combination With Systemic Therapy in Patients With High-risk Hepatocellular Carcinoma
Conditions
Interventions
Atezolizumab and Bevacizumab
Y90 + TKI
Locations
1
United States
Northwestern University
Chicago, Illinois, United States
Start Date
November 30, 2022
Primary Completion Date
July 1, 2026
Completion Date
July 1, 2026
Last Updated
October 20, 2025
NCT06811116
NCT06066138
NCT07485114
NCT06345508
NCT04380545
NCT07291076
Lead Sponsor
Northwestern University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions